Study Stopped
Terminated by mutual agreement between the site and sponsor
Clinical Study Verifying C-REX LapAid in Clinical Practice
A Multicenter Non-randomized Controlled Study (NRS) Evaluating the Use of Adaptive Anastomosis (CREX) in Clinical Practise
1 other identifier
interventional
13
1 country
1
Brief Summary
In colorectal surgery, hand suturing and stapling are routine methods for performing intestinal anastomoses, and these methods appear to be similar in terms of clinical safety. Despite several years of experience with surgical procedures as well as improvements to the medical devices, problems with disturbed anastomotic healing leading to leakage and stenosis after colorectal surgery remain a significant challenge for surgeons. A frequency of anastomotic leakage after stapling or suturing has been reported to range from 3% to 20%. In addition, preoperative radiotherapy has been shown to increase the risk of anastomotic leakage even further. The methods that are used today to detect leakages are unfortunately inaccurately and limited to monitoring symptoms, temperature, CRP-levels, and performing abdominal examinations and CT-scans. These clinical signs and parameters usually become apparent several days after onset of the leakage, which leads to a delayed diagnosis. Anastomotic leakage is not only a significant cause of increased morbidity of complications and mortality in patients, but also associated with increased risk of local recurrence and poor prognosis. Moreover, when reoperation is required to fix the leakage, a permanent stoma may be made at the level of the sigmoid colon and this procedure impacts live quality of patients negatively. Based on the above considerations, a novel, adaptive anastomotic method has been developed by CarpoNovum to achieve a safer anastomosis. The method's working name is C-REX Ring-locking Procedure. C-REX is referred to our Colorectal anastomotic rings for Re-join the intestinal ends and validate the anastomosis, with function of Extract samples for analysis and conduct X-ray through connected catheters. The novel adaptive anastomotic medical devices, C-REX LapAid and C-REX DMH/DMHC are easy to use, with unique possibility to control the anastomosis during and after surgery. The previous successful preclinical study encourages a clinical verification in patients undergoing colonic resection to evaluate the safety and performance of C-REX Ring-locking Procedure by use of C-REX LapAid and C-REX DMH/DMHC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 3, 2018
CompletedFirst Submitted
Initial submission to the registry
January 12, 2018
CompletedFirst Posted
Study publicly available on registry
January 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 10, 2019
CompletedApril 30, 2020
April 1, 2020
1.3 years
January 12, 2018
April 28, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence rate of complication related to the investigational device
Complications related to the investigational device, for instance anastomotic leakage, anastomotic bleeding, excess fluid in abdominal drainage, CT scan verified abdominal abscess
Up to 30 days after surgery
Secondary Outcomes (7)
Time to evacuation of the short-term implant
About 2 weeks after surgery
Time to first defecation
Up to 30 days after surgery
Time to first intestinal sounds
Up to 30 days after surgery
Time to passage of gas
Up to 30 days after surgery
Number of postoperative interventions related to the investigational device
Up to 30 days after surgery
- +2 more secondary outcomes
Other Outcomes (4)
Hemoglobin
Up to 30 days after surgery, when needed
WBC (white blood cell)
Up to 30 days after surgery, when needed
Physical examination
Up to 30 days after surgery
- +1 more other outcomes
Study Arms (1)
C-REX group
EXPERIMENTALAfter resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
Interventions
The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease. The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC
Eligibility Criteria
You may qualify if:
- Male or female age ≥18 years and ≤80 years.
- Planned resection due to benign or malign disease in the left colon (descending colon and sigmoid) or the upper rectum (15 cm above the anal rim).
- Cognitive ability to take part in the study and understand the information he/she receives about participating in the study.
- The patient has signed a written informed consent.
You may not qualify if:
- Urgent medical condition requiring immediate care.
- Current surgical conditions, such as intestinal obstruction or perforation, local or systemic infections, peritonitis, intestinal ischemia or severe dissemination (metastases) of cancer.
- Stenosis or other obstructions in the anal passage.
- Previous major abdominal surgery, previous radiation therapy to organs in abdomen or pelvis.
- Health condition classified as ASA III - VI .
- Albumin level less than 35 g/l.
- Inflammatory bowel disease (IBD) (ulcerative colitis or Crohn´s disease).
- Disease that requires more than one anastomosis during the surgical procedure.
- Treatment with cortisone and/or other immunosuppressive medications less than one month before surgery.
- Contraindications to general anaesthesia.
- Perioperative detection of extreme variants of intestinal diameters or wall thickness.
- Cognitive ability that limits the patient's ability to take part in the study and understand the information he/she received about participating in the study, or the patient does not agree to join the study.
- BMI \> 35.
- Myocardial infarct ≤ 6 months or sever heart disease.
- Severe embolic disease.
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Carponovum ABlead
- Fudan Universitycollaborator
Study Sites (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 2000032, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sanjun Cai, MD, PhD
Fudan University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 12, 2018
First Posted
January 19, 2018
Study Start
January 3, 2018
Primary Completion
April 30, 2019
Study Completion
May 10, 2019
Last Updated
April 30, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share